Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

lisocabtagene maraleucel

(LIH-soh-KAB-tuh-jeen MAR-uh-LOO-sel)
A treatment used for adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma, or certain types of large B-cell lymphoma that relapsed (came back) or did not get better after treatment with at least one or two lines of systemic therapy. It is also being studied in the treatment of other types of cancer. Lisocabtagene maraleucel is made using a patient’s T cells (a type of immune system cell). A gene for a special receptor called chimeric antigen receptor (CAR) is added to the T cells in the laboratory. These changed T cells called CAR T cells are grown in large numbers in the laboratory and given to the patient by infusion. Lisocabtagene maraleucel binds to a protein called CD19, which is found on most B-cell lymphoma cells. This helps the body’s immune system kill cancer cells. Lisocabtagene maraleucel is a type of cellular immunotherapy called CAR T-cell therapy. Also called Breyanzi.
Search NCI's Dictionary of Cancer Terms